Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DxTerity Diagnostics, a provider of genomic testing solutions, and the City of Hope National Medical Center in California, have announced that they will collaborate on the development of therapeutic applications for DxTerity's proprietary Neat technology. Terms of the agreement have not been disclosed.
Subscribe to our email newsletter
Neat is said to be a versatile genomics testing platform that enables gene-controlled ligation of oligonucleotide probes inside of cells. This highly specific technique will be used to develop in-situ assembled antisense therapeutics.
The DxTerity approach differs from normal antisense therapeutics because the initial materials are designed to be inactive requiring in-situ activation that is dependant on the expression of the target gene. If successful, the resulting new class of molecules could display specificity with reduced side effects.
Bob Terbrueggen, president and founder of DxTerity Diagnostics, said: “DxTerity is excited to be collaborating with City of Hope, whose recognized experience and expertise in developing drugs should accelerate the progress of this new class of antisense therapeutics. Our hope is that their well-developed model systems and scientific expertise will enable the rapid identification and evaluation of new drug candidates.”